- Datametrex AI (DM) subsidiary Medi-Call MD has officially launched a closed beta test for its Medi-Call health app
- Medi-Call is a comprehensive mobile application that allows Canadians to visit a doctor through their smartphones
- Once fully released, the Medi-Call app will be available for free in both the Apple App Store and the Google Play store
- Datametrex AI is a technology focused company with exposure to AI and machine learning
- Datametrex AI Ltd. (DM) opened trading at $0.17 per share
Datametrex AI (DM) subsidiary Medi-Call MD has officially launched a closed beta test for its Medi-Call health app.
Medi-Call is a comprehensive mobile application that allows Canadians to visit a doctor through their smartphones.
The closed beta test will be previewed in a webinar on October 28 and selected beta testers will be able to download the app on their mobile devices.
The Medi-Call app is a subscription service that connects patients with doctors via chat and video calls. Following a diagnosis, prescriptions can be provided as needed and sent to the patient’s designated pharmacy.
The app provides accessible healthcare to people who live in rural or isolated communities and make services more readily available and convenient for people with limited time, mobility, or transportation choices.
Marshall Gunter, CEO of Datametrex, commented,
“Medi-Call app is leveraging advanced technology to help bring accessible, affordable healthcare services to patients with doctors supporting Canadians to take greater ownership of their health and wellness outcomes outside of doctor offices and emergency rooms leading to improved health.”
He added, “Dr. Omar Sharif and his team at Medi-Call worked closely with the developers to provide another entry point to healthcare and consultation, which improves the patient’s experience.”
Once fully released, the Medi-Call app will be available for free in both the Apple App Store and the Google Play store.
Datametrex AI is a technology-focused company with exposure to AI and machine learning through its wholly-owned subsidiary, Nexalogy.
The company’s mission is to provide tools that support companies in fulfilling their operational goals, including health and safety, with predictive and preventive technologies.
Datametrex AI Ltd. (DM) opened trading at $0.17 per share.